Memorial Sloan Kettering Cancer Center State of the Art Ovarian Cancer Conference 2017

10 $

+ Include: 8 videos + 14 pdfs, size: 3.72 GB

+ Target Audience: clinicians including OB/GYNs, surgical/medical/gynecologic oncologists, primary care physicians

Description

+ Include: 8 videos + 14 pdfs, size: 3.72 GB

+ Target Audience: clinicians including OB/GYNs, surgical/medical/gynecologic oncologists, primary care physicians

+ Sample video: contact me for sample video

+ Information:

Date & Location

Thursday, October 5, 2017, 7:30 AM – 5:00 PM EST, Zuckerman Research Center 417 E 68th St, New York , NY

Specialties
Specialties – Diagnostic Radiology, General and Family Practice, Gynecologic Oncology, Hospice and Palliative Medicine, Internal Medicine, Medical Oncology, Nurse Practitioner, Nursing, Obstetrics and Gynecology, Physician Assistant, Solid Tumor Oncology, Surgical Oncology
Overview

Advances in women’s health research provide important opportunities to enhance the screening and prevention of ovarian cancer. New modalities in the treatment of the disease provide the ability to individualize therapy, accomplish best clinical outcomes, and optimize the patient experience. This course is designed to present the most current information on ovarian cancer with the goal of advancing the prevention, screening and treatment for ovarian cancer.

Target Audience
The target audience includes all clinicians, scientists and advocates interested in women’s health, and in optimizing the prevention, screening and treatment for ovarian cancer. Clinicians including OB/GYNs, surgical/medical/gynecologic oncologists, primary care physicians, physician assistants, nurse practitioners, nurses, fellows and residents and other healthcare professionals are welcome.

Sponsors

Memorial Sloan Kettering gratefully acknowledges the following organizations for providing independent medical educational grants or financial support for this live activity:

  • Bovie Medical
  • Intuitive Surgical
  • GeneDx
  • Medtronic
  • Myriad Genetic Laboratories
  • TESARO
  • ThermaSolutions, Inc.
Objectives
  1. Discuss new genetic panel testing and its implication, results of recent ovarian cancer screening trial, and strategies for ovarian cancer risk-reduction
  2. Present new algorithms for imaging and surgical case selection
  3. Evaluate emerging opportunities in clinical trial options, individualized treatment, and enhanced patient experience

 

+ Topics:

ERAS Debate- To Bowel Prep or Not…. and Other Sticky Issues.mp4
ERAS- Progressive Advances in Perioperative Management.mp4
ERAS- Progressive Advances in Perioperative Management.pdf
HIPEC – Toxicity and Outcomes.mp4
HIPEC – Toxicity and Outcomes.pdf
Leveraging the Stress Response in Ovarian Cancer Management.pdf
MSK Resectability Scoring for Primary Debulking Surgery.pdf
MSK_Ovarian_Cancer_Conference.pdf
New Genetic Risks- BRIP1, RAD51C, RAD51D and More.mp4
New Genetic Risks- BRIP1, RAD51C, RAD51D and More.pdf
New Strategies in Immunotherapy.pdf
NRG Updates and Highlights in Current Ovarian Cancer Clinical Trials.mp4
NRG Updates and Highlights in Current Ovarian Cancer Clinical Trials.pdf
Optimizing Upfront Debulking- Practical Applications and the Kaizen Approach.mp4
Optimizing Upfront Debulking- Practical Applications and the Kaizen Approach.pdf
PARP Inhibitors- The Story Continues.pdf
Section of Ovarian Cancer Surgery- Mission and Team Overview.pdf
Surgery for Recurrent Disease- Palliative or Therapeutic Intent.mp4
Surgery for Recurrent Disease- Palliative or Therapeutic Intent.pdf
Surgical Video- Radical Upper Abdominal Dissection.mp4
The Fallopian Tube and Ovarian Cancer Development.pdf
Welcome.pdf

Reviews

There are no reviews yet.

Be the first to review “Memorial Sloan Kettering Cancer Center State of the Art Ovarian Cancer Conference 2017”

Your email address will not be published. Required fields are marked *

− 1 = 2
Powered by MathCaptcha